Correction: Transient alteration of consciousness in spinal cord injury secondary to Baclofen use: a case report

Spinal Cord Series and Cases, 2023 · DOI: https://doi.org/10.1038/s41394-023-00601-6 · Published: January 1, 2023

Spinal Cord Injury Pharmacology Neurology

Simple Explanation

This is a correction to a previously published article regarding Baclofen use in spinal cord injury patients. The correction clarifies that Baclofen is a GABA receptor agonist, not an antagonist, as originally stated. This correction is important for the proper understanding and management of spasticity in patients.

Study Duration

Not specified

Participants

Not specified

Evidence Level

Not specified

Key Findings

1
The original article incorrectly stated that Baclofen is a GABA receptor antagonist.
2
The correction clarifies that Baclofen is, in fact, a GABA receptor agonist.
3
The original article has been corrected to reflect this change.

Research Summary

This document is a correction to a published case report. The correction addresses an error in the description of Baclofen's mechanism of action. The initial publication misidentified Baclofen as a GABA receptor antagonist. This has been updated to accurately state that Baclofen is a GABA receptor agonist. The correction ensures accurate information regarding the pharmacological action of Baclofen in the context of spasticity management following spinal cord injury.

Practical Implications

Clinical Accuracy

Ensures clinicians have correct information regarding Baclofen's mechanism for proper treatment.

Pharmacological Understanding

Promotes a clearer understanding of the drugs that are being used.

Future Research

Prevents propagation of incorrect information in future studies.

Study Limitations

1
Limited information provided in the correction itself
2
Only addresses one specific error
3
No new data presented

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury